Immuneering(IMRX.US)

Last Updated 19:00:00 ET
longbridge loading

Immuneering (IMRX) Gets a Buy from Chardan Capital

Tip Ranks·
US
IMRX
+2.66%
US
VHT
+0.27%
US
XBI
+3.88%
Tip Ranks·
US
IMRX
+2.66%
US
VHT
+0.27%
US
XBI
+3.88%

Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary

TradingView·
US
IMRX
+2.66%
US
LABU
+11.76%
US
IBB
+2.27%
TradingView·
US
IMRX
+2.66%
US
LABU
+11.76%
US
IBB
+2.27%

Immuneering | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
IMRX
+2.66%
Earnings Watch·
US
IMRX
+2.66%

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | IMRX Stock News

StockTitan·
US
IMRX
+2.66%
US
SBIO
+3.75%
US
FBT
+2.14%
StockTitan·
US
IMRX
+2.66%
US
SBIO
+3.75%
US
FBT
+2.14%

Immuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1

nasdaq·
US
IMRX
+2.66%
US
IBB
+2.27%
US
BBH
+0.96%
nasdaq·
US
IMRX
+2.66%
US
IBB
+2.27%
US
BBH
+0.96%

Immuneering Presents Encouraging CtDNA Data For Atebimetinib In Treating Cancer

nasdaq·
US
IMRX
+2.66%
US
XBI
+3.88%
US
IBB
+2.27%
nasdaq·
US
IMRX
+2.66%
US
XBI
+3.88%
US
IBB
+2.27%

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026

Tip Ranks·
US
IMRX
+2.66%
US
BIB
+4.98%
US
BBH
+0.96%
Tip Ranks·
US
IMRX
+2.66%
US
BIB
+4.98%
US
BBH
+0.96%
© 2026 Longbridge｜Disclaimer